Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in gout.

Bursill D, Taylor WJ, Terkeltaub R, Kuwabara M, Merriman TR, Grainger R, Pineda C, Louthrenoo W, Edwards NL, Andrés M, Vargas-Santos AB, Roddy E, Pascart T, Lin CT, Perez-Ruiz F, Tedeschi SK, Kim SC, Harrold LR, McCarthy G, Kumar N, Chapman PT, Tausche AK, Vazquez-Mellado J, Gutierrez M, Pinheiro GDRC, Richette P, Pascual E, Fisher MC, Burgos-Vargas R, Robinson PC, Singh JA, Jansen TL, Saag KG, Slot O, Uhlig T, Solomon DH, Keenan RT, Scire CA, Biernat-Kaluza E, Dehlin M, Nuki G, Schlesinger N, Janssen M, Stamp LK, Sivera F, Reginato AM, Jacobsson L, Lioté F, Ea HK, Rosenthal A, Bardin T, Choi HK, Hershfield MS, Czegley C, Choi SJ, Dalbeth N.

Arthritis Care Res (Hoboken). 2018 May 25. doi: 10.1002/acr.23607. [Epub ahead of print]

PMID:
29799677
2.

The British Society for Rheumatology Guideline for the Management of Gout.

Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, Jenkins W, Jordan KM, Mallen CD, McDonald TM, Nuki G, Pywell A, Zhang W, Roddy E; British Society for Rheumatology Standards, Audit and Guidelines Working Group.

Rheumatology (Oxford). 2017 Jul 1;56(7):1246. doi: 10.1093/rheumatology/kex250. No abstract available.

PMID:
28605531
3.

The British Society for Rheumatology Guideline for the Management of Gout.

Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, Jenkins W, Jordan KM, Mallen CD, McDonald TM, Nuki G, Pywell A, Zhang W, Roddy E; British Society for Rheumatology Standards, Audit and Guidelines Working Group.

Rheumatology (Oxford). 2017 Jul 1;56(7):1056-1059. doi: 10.1093/rheumatology/kex150. No abstract available. Erratum in: Rheumatology (Oxford). 2017 Jul 1;56(7):1246.

PMID:
28549195
4.

The British Society for Rheumatology Guideline for the Management of Gout.

Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, Jenkins W, Jordan KM, Mallen CD, McDonald TM, Nuki G, Pywell A, Zhang W, Roddy E; British Society for Rheumatology Standards, Audit and Guidelines Working Group.

Rheumatology (Oxford). 2017 Jul 1;56(7):e1-e20. doi: 10.1093/rheumatology/kex156. No abstract available. Erratum in: Rheumatology (Oxford). 2017 Jul 1;56(7):1246.

PMID:
28549177
5.

Improving management of gout in primary care: a new UK management guideline.

Mallen CD, Davenport G, Hui M, Nuki G, Roddy E.

Br J Gen Pract. 2017 Jun;67(659):284-285. doi: 10.3399/bjgp17X691313. No abstract available.

6.

Current management of gout: practical messages from 2016 EULAR guidelines.

Nuki G, Doherty M, Richette P.

Pol Arch Intern Med. 2017 Apr 28;127(4):267-277. doi: 10.20452/pamw.4001. Epub 2017 Apr 21.

7.

2016 updated EULAR evidence-based recommendations for the management of gout.

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T.

Ann Rheum Dis. 2017 Jan;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707. Epub 2016 Jul 25. Review.

PMID:
27457514
8.

2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Lioté F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vaquez-Mellado J, Yarows SA, Taylor WJ.

Ann Rheum Dis. 2015 Oct;74(10):1789-98. doi: 10.1136/annrheumdis-2015-208237. Erratum in: Ann Rheum Dis. 2016 Feb;75(2):473.

9.

2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Lioté F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vazquez-Mellado J, Yarows SA, Taylor WJ.

Arthritis Rheumatol. 2015 Oct;67(10):2557-68. doi: 10.1002/art.39254. Erratum in: Arthritis Rheumatol. 2016 Feb;68(2):515. Vaquez-Mellado, Janitzia [corrected to Vazquez-Mellado, Janitzia].

10.

Improving cardiovascular and renal outcomes in gout: what should we target?

Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, Punzi L, So AK, Bardin T.

Nat Rev Rheumatol. 2014 Nov;10(11):654-61. doi: 10.1038/nrrheum.2014.124. Epub 2014 Aug 19. Review.

PMID:
25136785
11.

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.

MacDonald TM, Ford I, Nuki G, Mackenzie IS, De Caterina R, Findlay E, Hallas J, Hawkey CJ, Ralston S, Walters M, Webster J, McMurray J, Perez Ruiz F, Jennings CG; Members of the FAST Study Group.

BMJ Open. 2014 Jul 10;4(7):e005354. doi: 10.1136/bmjopen-2014-005354.

12.

Up-titration of allopurinol in patients with gout.

Jennings CG, Mackenzie IS, Flynn R, Ford I, Nuki G, De Caterina R, Riches PL, Ralston SH, MacDonald TM; FAST study group.

Semin Arthritis Rheum. 2014 Aug;44(1):25-30. doi: 10.1016/j.semarthrit.2014.01.004. Epub 2014 Jan 23.

PMID:
24560169
13.

An appraisal of the 2012 American College of Rheumatology Guidelines for the Management of Gout.

Nuki G.

Curr Opin Rheumatol. 2014 Mar;26(2):152-61. doi: 10.1097/BOR.0000000000000034. Review.

PMID:
24492863
14.

Cost-effectiveness of febuxostat in chronic gout.

Beard SM, von Scheele BG, Nuki G, Pearson IV.

Eur J Health Econ. 2014 Jun;15(5):453-63. doi: 10.1007/s10198-013-0486-z. Epub 2013 May 30. Erratum in: Eur J Health Econ. 2014 Nov;15(8):897.

PMID:
23719971
15.

Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey.

Khanna PP, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, Vietri J, Khanna D.

Health Qual Life Outcomes. 2012 Sep 22;10:117. doi: 10.1186/1477-7525-10-117.

16.

Gout: why is this curable disease so seldom cured?

Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, So AK, Bardin T.

Ann Rheum Dis. 2012 Nov;71(11):1765-70. doi: 10.1136/annrheumdis-2012-201687. Epub 2012 Aug 3. Review.

PMID:
22863577
17.

OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009.

Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P.

Osteoarthritis Cartilage. 2010 Apr;18(4):476-99. doi: 10.1016/j.joca.2010.01.013. Epub 2010 Feb 11. Review.

18.

Signalling cascades in mechanotransduction: cell-matrix interactions and mechanical loading.

Ramage L, Nuki G, Salter DM.

Scand J Med Sci Sports. 2009 Aug;19(4):457-69. doi: 10.1111/j.1600-0838.2009.00912.x. Epub 2009 Jun 15. Review.

PMID:
19538538
19.
20.

Colchicine: its mechanism of action and efficacy in crystal-induced inflammation.

Nuki G.

Curr Rheumatol Rep. 2008 Jul;10(3):218-27. Review.

PMID:
18638431
21.

In memoriam: J. Edwin Seegmiller, M.D. (1920-2006).

Becker MA, Friedmann T, Raivio KO, Hershfield MS, Nuki G.

Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):554-6. doi: 10.1080/15257770802135638. No abstract available.

PMID:
18600502
22.

Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis.

Galarraga B, Ho M, Youssef HM, Hill A, McMahon H, Hall C, Ogston S, Nuki G, Belch JJ.

Rheumatology (Oxford). 2008 May;47(5):665-9. doi: 10.1093/rheumatology/ken024. Epub 2008 Mar 24.

PMID:
18362100
23.

OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines.

Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P.

Osteoarthritis Cartilage. 2008 Feb;16(2):137-62. doi: 10.1016/j.joca.2007.12.013. Review.

24.

Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005.

Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G.

Ann Rheum Dis. 2008 Jul;67(7):960-6. Epub 2007 Nov 2.

25.

OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence.

Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P.

Osteoarthritis Cartilage. 2007 Sep;15(9):981-1000. Epub 2007 Aug 27. Review.

26.

British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.

Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, Hingorani A, Jaques R, Nuki G; British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG).

Rheumatology (Oxford). 2007 Aug;46(8):1372-4. Epub 2007 May 23. No abstract available.

PMID:
17522099
27.

Evidence for JNK-dependent up-regulation of proteoglycan synthesis and for activation of JNK1 following cyclical mechanical stimulation in a human chondrocyte culture model.

Zhou Y, Millward-Sadler SJ, Lin H, Robinson H, Goldring M, Salter DM, Nuki G.

Osteoarthritis Cartilage. 2007 Aug;15(8):884-93. Epub 2007 Apr 3.

28.

A concise history of gout and hyperuricemia and their treatment.

Nuki G, Simkin PA.

Arthritis Res Ther. 2006;8 Suppl 1:S1. Epub 2006 Apr 12. Review.

29.

Treatment of crystal arthropathy--history and advances.

Nuki G.

Rheum Dis Clin North Am. 2006 May;32(2):333-57, vi. Review.

PMID:
16716883
30.

EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentão J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gòrska I; EULAR Standing Committee for International Clinical Studies Including Therapeutics.

Ann Rheum Dis. 2006 Oct;65(10):1301-11. Epub 2006 May 17. Review.

31.

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentão J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gòrska I; EULAR Standing Committee for International Clinical Studies Including Therapeutics.

Ann Rheum Dis. 2006 Oct;65(10):1312-24. Epub 2006 May 17. Review.

32.

Association of low general health status, measured prospectively by Euroqol EQ5D, with osteoporosis, independent of a history of prior fracture.

Dhillon V, Hurst N, Hannan J, Nuki G.

Osteoporos Int. 2005 May;16(5):483-9. Epub 2004 Jul 28.

PMID:
15875094
33.

A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.

van Holten J, Pavelka K, Vencovsky J, Stahl H, Rozman B, Genovese M, Kivitz AJ, Alvaro J, Nuki G, Furst DE, Herrero-Beaumont G, McInnes IB, Musikic P, Tak PP.

Ann Rheum Dis. 2005 Jan;64(1):64-9. Epub 2004 Jul 8.

34.

The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report.

Boonen S, Rizzoli R, Meunier PJ, Stone M, Nuki G, Syversen U, Lehtonen-Veromaa M, Lips P, Johnell O, Reginster JY.

Osteoporos Int. 2004 Jul;15(7):511-9. Review.

PMID:
15069595
35.

Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.

Abadie E, Ethgen D, Avouac B, Bouvenot G, Branco J, Bruyere O, Calvo G, Devogelaer JP, Dreiser RL, Herrero-Beaumont G, Kahan A, Kreutz G, Laslop A, Lemmel EM, Nuki G, Van De Putte L, Vanhaelst L, Reginster JY; Group for the Respect of Excellence and Ethics in Science.

Osteoarthritis Cartilage. 2004 Apr;12(4):263-8. Review.

36.
37.

Activation of Integrin-RACK1/PKCalpha signalling in human articular chondrocyte mechanotransduction.

Lee HS, Millward-Sadler SJ, Wright MO, Nuki G, Al-Jamal R, Salter DM.

Osteoarthritis Cartilage. 2002 Nov;10(11):890-7.

39.

A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.

Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, Cohen P, Calabrese LH, Dickler H, Merkel PA, Fortin P, Flynn JA, Locker GA, Easley KA, Schned E, Hunder GG, Sneller MC, Tuggle C, Swanson H, Hernández-Rodríguez J, Lopez-Soto A, Bork D, Hoffman DB, Kalunian K, Klashman D, Wilke WS, Scheetz RJ, Mandell BF, Fessler BJ, Kosmorsky G, Prayson R, Luqmani RA, Nuki G, McRorie E, Sherrer Y, Baca S, Walsh B, Ferland D, Soubrier M, Choi HK, Gross W, Segal AM, Ludivico C, Puechal X; International Network for the Study of Systemic Vasculitides.

Arthritis Rheum. 2002 May;46(5):1309-18.

40.

Differential responses of chondrocytes from normal and osteoarthritic human articular cartilage to mechanical stimulation.

Salter DM, Millward-Sadler SJ, Nuki G, Wright MO.

Biorheology. 2002;39(1-2):97-108.

PMID:
12082272
41.

Integrin-interleukin-4 mechanotransduction pathways in human chondrocytes.

Salter DM, Millward-Sadler SJ, Nuki G, Wright MO.

Clin Orthop Relat Res. 2001 Oct;(391 Suppl):S49-60. Review.

PMID:
11603724
44.

Altered electrophysiological responses to mechanical stimulation and abnormal signalling through alpha5beta1 integrin in chondrocytes from osteoarthritic cartilage.

Millward-Sadler SJ, Wright MO, Lee H, Caldwell H, Nuki G, Salter DM.

Osteoarthritis Cartilage. 2000 Jul;8(4):272-8.

45.

Macrovascular disease and systemic sclerosis.

Ho M, Veale D, Eastmond C, Nuki G, Belch J.

Ann Rheum Dis. 2000 Jan;59(1):39-43.

46.

CD44 is involved in selective leucocyte extravasation during inflammatory central nervous system disease.

Brennan FR, O'Neill JK, Allen SJ, Butter C, Nuki G, Baker D.

Immunology. 1999 Nov;98(3):427-35.

47.

Osteoarthritis: a problem of joint failure.

Nuki G.

Z Rheumatol. 1999 Jun;58(3):142-7. Review.

PMID:
10441841
48.

Successful treatment of severe muscle necrosis with intravenous immunoglobulin.

McRorie E, King M, Richmond R, Smith G, Jobanputra P, Nuki G.

J Rheumatol. 1999 Jun;26(6):1411-3.

PMID:
10381067
49.

Integrin-regulated secretion of interleukin 4: A novel pathway of mechanotransduction in human articular chondrocytes.

Millward-Sadler SJ, Wright MO, Lee H, Nishida K, Caldwell H, Nuki G, Salter DM.

J Cell Biol. 1999 Apr 5;145(1):183-9.

50.

Supplemental Content

Support Center